Literature DB >> 24412146

Intraoperative blood salvage in revision total hip arthroplasty: who benefits most?

Max Greenky1, Julie Shaner1, Mohammad R Rasouli1, Seung-Beom Han1, Javad Parvizi1, William J Hozack1.   

Abstract

The purpose of the present study was to identify factors that predict reinfusion following intraoperative blood salvage (IOBS). We retrospectively identified 298 patients who underwent aseptic revision total hip arthroplasty at our institution between February 2005 and January 2007. Of these, 160 (53.7%) received reinfusion from IOBS. In the reinfusion group, an average of 850 mL (range, 300-4300) of fluid was collected and an average of 270 mL (range, 135-1350) of red blood cells was returned. Exchange of both the femoral and acetabular components, use of a trochanteric osteotomy, increased body mass index, and advanced age were associated with reinfusion. Based on these results, surgeons may consider using IOBS on patients with these preoperative characteristics.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood loss; intraoperative blood salvage; revision total hip arthroplasty; transfusion

Mesh:

Year:  2013        PMID: 24412146     DOI: 10.1016/j.arth.2013.12.009

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  9 in total

1.  Use of a fibrin sealant within a blood-saving protocol in patients undergoing revision hip arthroplasty: effects on post-operative blood transfusion and healthcare-related cost analysis.

Authors:  Marco Scardino; Federica Martorelli; Tiziana D'Amato; Giorgia Fenocchio; Vincenzo Simili; Guido Grappiolo; Berardo Di Matteo; Elizaveta Kon; Michele Lagioia
Journal:  Int Orthop       Date:  2019-01-23       Impact factor: 3.075

Review 2.  Reducing perioperative blood loss with antifibrinolytics and antifibrinolytic-like agents for patients undergoing total hip and total knee arthroplasty.

Authors:  Bhaveen H Kapadia; Barrett B Torre; Nicholas Ullman; Andrew Yang; Matthew A Harb; Preston W Grieco; Jared M Newman; Steven F Harwin; Aditya V Maheshwari
Journal:  J Orthop       Date:  2019-07-02

3.  Acetabular defect management and revision arthroplasty via the direct anterior approach.

Authors:  Boris Michael Holzapfel; Kristoff Corten; Tyler Goldberg; Maximilian Rudert; Michael Nogler; Joseph Moskal; Martin Thaler
Journal:  Oper Orthop Traumatol       Date:  2022-06-09       Impact factor: 1.154

4.  Effectiveness of an autologous transfusion system following cemented and non-cemented revisions of total hip arthroplasty.

Authors:  Nael Hawi; Daniel Oliver Kendoff; Udo Hessling; Carl Haasper; Thorsten Gehrke; Mustafa Citak
Journal:  Int Orthop       Date:  2014-05-11       Impact factor: 3.075

5.  Blood loss and allogeneic transfusion for surgical treatment of periprosthetic joint infection: a comparison of one- vs. two-stage exchange total hip arthroplasty.

Authors:  Ahmad Shoib Sharqzad; Camila Cavalheiro; Akos Zahar; Christian Lausmann; Thorsten Gehrke; Daniel Kendoff; Javad Parvizi; Mustafa Citak
Journal:  Int Orthop       Date:  2018-09-05       Impact factor: 3.075

Review 6.  Patient Blood Management in Hip Replacement Arthroplasty.

Authors:  Jong Hee Lee; Seung Beom Han
Journal:  Hip Pelvis       Date:  2015-12-30

7.  Incidence and risk factors for blood transfusion in simultaneous bilateral total hip arthroplasty.

Authors:  Xing Wang; Qiang Huang; Fuxing Pei
Journal:  Jt Dis Relat Surg       Date:  2021-11-19

8.  Risk Factors for the Postoperative Transfusion of Allogeneic Blood in Orthopedics Patients With Intraoperative Blood Salvage: A Retrospective Cohort Study.

Authors:  Jia-Hua Tang; Yi Lyu; Li-Ming Cheng; Ying-Chuan Li; Da-Ming Gou
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

9.  Intraoperative cell salvage use reduces the rate of perioperative allogenic blood transfusion in patients undergoing periacetabular osteotomy.

Authors:  Michael van der Merwe; Nicholas J Lightfoot; Jacob T Munro; Matthew J Boyle
Journal:  J Hip Preserv Surg       Date:  2019-10-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.